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Abstract
BACKGROUND: Selective internal radiation therapy (SIRT) with 90Y-microspheres infusion into the hepatic artery is a novel 
method for palliative treatment of primary and metastatic liver cancer. The post-procedural 90Y dose estimation in the liver is 
very difficult because direct measurement of b particles is not possible with SPECT/CT. New methods are needed to assess 
the 90Y-microspheres liver distribution. In the present paper we evaluate the 90Y-PET for these purposes.
MATERIALS AND METHODS: A GE Discovery ST PET/CT scanner with a copper ring protected the gantry was used for ima-
ges acquisition. For SPECT/CT imaging, a GE Infinia VCHWK4 with HEPG collimators was used.
The liver 90Y-microspheres (SIR-Spheres, SIRTEX, Australia) dose distribution after selective internal radiotherapy treatment 
was evaluated in three patients (9 lesions in total). The activity of 90Y-microspheres delivered into the liver ranged from 1.0 GBq 
to 2.2 GBq. The correlations between liver lesions detected with 90Y-PET, 99mTc-MAA and 90-bremsstrahlung were investigated 
and compared with CT images obtained before and after the procedure.
RESULTS: The mean T/N ratio was 2.7 in 99mTc-MAA, 2.3 in 90Y-bremsstrahlung and 3.6 in 90Y-PET. The mean 90Y absorbed 
dose in tumor was 133 Gy, 112 Gy, and 187 Gy, respectively. The mean liver tissue radiation was 15.5 Gy. According to 
RECIST criteria, one PR (mCRC) and two SD were observed (mCRC and PC). Time to progression was 217 and 117 days in 
two patients with mCRC and 214 days in the patient with PC.
CONCLUSIONS: 90Y-PET/CT images give crucial information regarding 90Y-microspheres distribution and dosimetry and may 
serve as a predictor of efficiency of radioembolisation.
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Background
Selective internal radiation therapy (SIRT) with direct 90Y-micro-
spheres infusion into the hepatic artery is a novel, promising method 
for palliative treatment of primary and metastatic liver cancer [1, 2] 
The most important problem associated with this therapy is to cal-
culate an adequate activity of 90Y-microspheres, which can destroy 
liver tumors while sparing healthy liver tissue [3, 4]. The 99mTc-MAA 
scans are performed in order to calculate a 90Y dose and to predict 
a post infusion 90Y-microspheres distribution profile between the 
liver parenchyma and tumor compartments (the T/N ratio). The 
post procedural 90Y dose estimation in liver is very difficult because 
direct measurement of b particles is not possible with SPECT/CT. 
Thus, 90Y bremsstrahlung single-photon emission computed to-
mography/computed tomography (SPECT/CT) is performed to 
assess post-treatment 90Y-microspheres distribution [3, 5]. In real-
ity, there are two ways to calculate dosimetry after SIRT. The first 
one is the MIRD equation based on the assumption of uniform 90Y 
distribution between the tumor and liver tissue compartments [6]. 
The second one is Monte Carlo simulation in which SPECT/CT 
images are used to obtain the isodoses curves and histograms of 
the target liver lesions [7]. For improvement of SIRT treatment 
results a detailed knowledge about 90Y-microspheres distribution 
within the liver is required [3]. This way patients prone to potential 
radiation-induced liver disease (RILD) or patients with non-curative 
tumor dose may be selected immediately after a SIRT procedure. In 
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the present paper, we assessed the 90Y-PET/CT method as an alter-
native for the 99mTc-MAA and 90Y-SPECT (bremsstrahlung) images in 
clinical studies.
Materials and methods
Patient studies
Three patients (2 males, 1 female) were treated with 90Y mi-
crospheres selective internal radioembolisation. All patients with 
unresectable liver metastases had adequate performance sta-
tus and acceptable liver and renal function. Two patients had 
colorectal liver metastasis (mCRC) and one had metastasis from 
pancreatic cancer. A total of nine tumors was evaluated, 7 mCRC 
and 2 pancreatic cancer cases. The study was approved by Ethics 
Committee. All the patients were included in the study after signing 
a written informed consent.
Image evaluation
The patients were assessed before and after selective internal 
radioembolisation (SIRT) with computed tomography (CT). The 
whole liver volume, the liver tumors longest diameter and volume 
were collected. The 90Y-PET studies were performed between 8 and 
48 hours after resin microspheres administration into the liver. The 
Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) were 
used to evaluate liver tumors response [8]. The correlations be-
tween the target liver lesions detected with 90Y-PET, 90Y-SPECT and 
99mTc-MAA were investigated and compared with CT images ob-
tained one month before and two or three months after procedure. 
The tumor to normal liver tissue ratio (T/N ratio) in 99mTc-MAA, in 
90Y-SPECT and in 90Y-PET for each selected lesion was calculated. 
Based on the data, the absorbed dose for the liver parenchyma 
and for each target liver tumor was calculated using the internal 
dosimetry schema of the Medical Internal Dose (MIRD) Committee 
of Society of Nuclear Medicine [6]. The absorbed dose was calcu-
lated using the T/N ratio in 99Tc-MAA, in 90Y-bremsstrahlung and 
in 90Y-PET. The target lesion in the liver was described as a lesion 
with the longest diameter of minimum 10 mm and clearly visible 
on CT, 90Y-PET, 99Tc MAA SPECT and 90Y-SPECT. A GE Discovery ST 
PET/CT scanner with a copper ring protected the gantry was used 
for images acquisition. The ring thickness was 2 mm. The ring width 
was sufficient to cover the area of the detector (and equal to the axial 
FOV). The time of a single 90Y-PET scan was 20 min (one patient) 
and 30 min (two patients). The role of the copper ring was to ab-
sorb the bremsstrahlung photons and to prevent saturations of the 
detectors. A GE Infinia VCHWK4 with HEPG collimators was used 
for SPECT/CT imaging. The energy window was 140 keV ± 100%.
SIRT procedure
The radioembolization procedure was conducted in line with 
guidelines approved by panel experts [3, 5].
Candidates for radioembolization therapy were qualified by 
a multidisciplinary team consisting of interventional radiologists, 
oncologists, nuclear medicine specialists and surgeons in line 
with strict inclusion and exclusion criteria, which were published 
previously [3, 5].
During the pre-treatment procedure, selective coil embolization 
of the gastroduodenal artery, right gastric artery and gallbladder 
artery were performed. The hepatopulmonary shunt, a potential 
gastrointestinal leak and the tumor to liver ratio were assessed after 
SPECT 99mTc-MAA. An activity of 4mci 99Tc MAA was administered 
into the hepatic artery. The Body Surface Area Method was used 
for the patients’ 90Y-microspheres dose calculation [5]. All the 
patients were treated with 90Y biocompatible, not biodegradable 
SIR-Spheres microspheres (Sirtex Medical Inc., Australia). The 90Y 
is a pure beta emitter with a liver tissue penetration of 2.5 mm and 
average energy of 0.94 MeV and a half-life of 2.67 days. The average 
resin microspheres’ diameter is 35 ± 5 mm [3, 5]. The SIRT proce-
dure was performed after superselective catheterization of hepatic 
artery branches by a slow, controlled 90Y microspheres injection. 
All the patients received whole liver treatment. After the therapy, 
bremsstrahlung with SPECT and 90Y-PET images were made to 
check 90Y-microspheres liver dose deposition.
Results
All SIRT procedures were made with technical success. The 
whole dose prescribed for each patient was administered. There 
were no serious adverse events (SAE) observed. After the therapy, 
two patients had transient nausea, vomiting and mild pain in the liver 
region which required only symptomatic treatment. The details of 
clinical and treatment data are summarized in Table 1.
A total of nine tumor target lesions were evaluated with imag-
ing methods. Taking into consideration the response rate for each 
solid tumor, two CR, two PR and three SD were observed for seven 
mCRC at first follow-up. For two pancreatic lesions SD was found. 
The 90Y absorbed dose in the liver tissue ranged from 8.5 Gy to 
25.8 Gy (mean 15.5 Gy). The mean T/N ratio was 2.7 in 99mTc-MAA, 
2.3 in 90Y-SPECT and 3.6 in 90Y-PET. The mean 90Y absorbed dose 
in tumor was 133 Gy, 112 Gy, and 187 Gy, respectively. All the 
tumors except one had sufficient (> 70 Gy) absorbed dose cal-
culated using the T/N ratio revealed in imaging. Only one mCRC 
lesion (No 2) had absorbed dose lower than 70 Gy (based on 
MAA T/N ratio). In this case a complete response was confirmed 
in the first follow-up. The image response parameters, the T/N 
ratio and the estimated (MIRD) dose calculations for each tumor 
are summarized in Table 2.
Table 1. Patients’ data
Parameter Patient 1 Patient 2 Patient 3
Gender Woman Man Man
Age 49 61 38
Liver metastases mCRC mCRC Pancreatic
Number 4 3 2
Diameter [cm] 21 (10–36) 54 (22–85) 98 (80–117)
Cancer volume [ml] 36 420 339
Liver volume [ml] 920 2376 1689
Delivered dose of 90Y [GBq] 1.0 1.9 2.2
AE
SAE 0 0 0
Mild (nausea, pain) 1 1 0
RECIST
First follow-up PR SD SD
Time to progression (days) 217 117 214
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Discussion
In the recent years, there has been a growing interest observed 
in the use of 90Y microspheres for regional liver tumor therapy. 
Promising treatment results such as improvements of time to 
progression, median overall survival and safety profile are an en-
couragement for further development of this method [1, 9–11]. 
Although we are aware that one of the main limitations of our study 
is a small group of patients, we can also confirm high efficiency 
of this therapy. We noticed one partial response and two stable 
diseases in our study. The time to progression ranged from 117 
to 217 days in colorectal metastases and 214 days in pancreatic 
cancer metastases. There are no serious adverse events associated 
with the therapy. In our opinion, there is still room for improvement 
of results in this treatment. The first way is to treat patients as soon 
as possible. At present, results of prospective randomized mul-
ticenter trials are expected (i.e. SIRFLOX), in which radioembo-
lisation in first line treatment is evaluated [12]. The second way 
is to improve knowledge on 90Y-microspheres liver distribution, 
especially 90Y liver dosimetry. The background for intra-arterial 
90Y-microspheres therapy is a special type of vascular anatomy of 
the liver. The majority of liver tumors’ blood supply originates from 
the hepatic artery branches, then the portal vein (about 80–100% 
of their supply for tumors >3 mm) [13]. It is estimated that a dose 
higher than 70 Gy is required to destroy most of the liver tumors. 
High 90Y-microspheres concentration within liver cancer leads to 
their destruction by way of ionizing radiation and embolization. 
The former has a crucial importance for the therapy [14]. The main 
limitation of radioembolisation is low liver tissue tolerance to radia-
tion, with a possibility of serious adverse events after irradiation 
higher than 30 Gy [14, 15]. In our study, the radiation of the liver 
was estimated from 8.4 Gy to 25.8 Gy (mean 15.5 Gy) based on 
the MIRD formula and no serious side effects were reported (i.e. 
RILD). To predict post-infusion 90Y-microspheres’ distribution within 
the liver parenchyma 99mTc-MAA scans are taken. Nevertheless, the 
real distribution of the 90Y-microspheres might be different from the 
99mTc-MAA because of a higher albumin diameter and intra-hepatic 
blood flow variations [3, 5, 16]. After the therapy, 90Y-bremsstrahlung 
single-photon emission computed tomography/computed tomog-
raphy (SPECT/CT) is performed to evaluate the real distribution of 
90Y-microspheres [3, 5]. Unfortunately, insufficient spatial resolution 
of 90Y-bremsstrahlung images is a main limitation of this method 
and can lead to inaccurate evaluation of 90Y-microspheres dis-
tribution [17]. To evaluate intra-hepatic 90Y administration some 
authors use a 99mTc-MAA injection immediately after a SIRT proce-
dure [18]. However, in our opinion, embolic effects of resin micro-
spheres may lead to inaccurate 99mTc-MAA deposition in the liver and 
conclusions based on this method may therefore be misleading. 
A novel approach to assessment of radioembolisation effects con-
sists in taking 90Y PET images [19, 20]. Although 90Y is traditionally 
considered a pure b-emitter, its decay has a minor branch to the 0+ 
first excited state of 90Zr at 1.78 MeV. De-excitation consists in emis-
sion of either a conversion electron or an internal e–e+ pair creation. 
It happens in 32 out of 1 million decays and might be imaged with 
PET [20, 21]. We assessed the 90Y-PET method as an alternative 
for the 99mTc-MAA and bremsstrahlung SPECT/CT images in clinical 
studies. We performed a 90Y-PET test between 8 to 24 hours after 
SIRT and we did not observe deterioration of image quality over 
time. As the 90Y half-life is 2.67 days, the PET scan should be taken 
within this time limit in our opinion [3, 13, 21]. The time of a single 
PET imaging was 20 min in one case and 30 min in the next two 
patients. To obtain better image results we suggest taking a PET 
scan lasting 30 min for an administered dose ranging 1.2–2.2 
GBq of 90Y-microspheres. In order to protect the gantry detectors, 
we used a copper ring to absorb photons of low energy and we 
observed that 2 mm thickness of the ring is sufficient to achieve 
this aim. However, some authors do not use any protection and 
they have not noticed its saturation with total activity of 2.0 GBq. Yet, 
sometimes a higher dose may be needed for a patient’s treatment 
and we suggest more caution in such cases [22].
We noticed a similar T/N ratio calculated using 99mTc-MAA and 
bremsstrahlung SPECT/CT images for most liver tumors and con-
siderable differences when we compare them with the 90Y-PET-re-
vealed T/N ratio. The mean T/N ratio was 2.7 in 99mTc-MAA, 2.3 
in 90Y-SPECT and 3.6 in 90Y-PET. The mean 90Y absorbed dose in 
tumor was 133 Gy, 112 Gy, and 187 Gy, respectively. It leads also 
to significant differences between the calculated 90Y liver tumors’ 
absorbed doses. We can see doses, which are 2–3 times higher 
when estimated with the 90Y-PET T/N ratio. It means that the dose 
required to destroy the tumor (approximately 70-90 Gy) is signifi-
cantly exceeded [14, 15]. According to our study, tumor absorbed 
doses calculated with 90Y-PET ranged from 144 Gy to 283 Gy, but 
when we consider tumor treatment results we can see mostly 
stable disease in overall response rate. Therefore, the absorbed 
doses calculated on the basis of the 99mTc-MAA and bremsstrahl-
ung SPECT/CT ratio ranging from 64 Gy to 183 Gy (except tumor 
Table 2. The T/N ratio and estimated adsorbed dose for each tumor
No TUMOR SIZE [mm] T/N 1 T/N 2 T/N 3 AD 1 AD 2 AD 3 RECIST
1 mCRC 36 1.6 1.9 3.8 85 101 201 PR
2 mCRC 20 1.2 1.4 3.4 63 74 174 PR
3 mCRC 20 1.4 1.8 4.2 74 95 223 CR
4 mCRC 10 1.7 1.4 2.5 90 74 132 CR
5 mCRC 79 3.2 2.5 4.0 174 95 152 SD
6 mCRC 75 2.9 2.4 3.9 121 91 148 SD
7 mCRC 32 5.0 2.9 3.8 110 110 144 SD
8 PC 80 5.7 3 2.8 359 189 226 SD
9 PC 117 1.9 3.6 4.4 120 182 283 SD
T/N 1 — T/N in MAA, T/N 2 — T/N in 90Y SPECT, T/N 3 — T/N in 90Y-PET, AD 1 — adsorbed dose in MAA, AD 2 — adsorbed dose in 90Y-SPECT, AD 3 — adsorbed dose in 90Y-PET
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No. 8) seem to be more close to reality. One of the explanations of 
these results may be lower sensitivity of 90Y-PET/CT compared to 
90Y-bremsstrahlung [20]. Thus, to assess the real T/N ratio based 
on 90Y-PET/CT, further studies are necessary (Figure 1). On the other 
hand, its resolution and contrast are much better and 90Y-PET/CT 
imaging may be used not only to detect liver lesions after radio-
embolisation, but also to distinguish a necrosis area within solid 
tumors. Better resolution of this method may help to find out leaks of 
90Y microspheres to the digestive tract in our opinion [17, 20]. From 
our point of view, the possibility of estimation of radiation dose in 
liver lesions is very interesting.
Conclusion
90Y-PET/CT images give crucial information regarding 90Y-micro-
spheres distribution and dosimetry and may serve as a predictor 
of efficiency of radioembolisation.
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